Literature DB >> 11600360

Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures.

L C McDonald1, F J Chen, H J Lo, H C Yin, P L Lu, C H Huang, P Chen, T L Lauderdale, M Ho.   

Abstract

A survey of 1,203 Escherichia coli isolates from 44 hospitals in Taiwan revealed that 136 (11.3%) isolates were resistant to fluoroquinolones and that another 261 (21.7%) isolates had reduced susceptibility. Resistance was more common in isolates responsible for hospital-acquired (mostly in intensive care units) infections (17.5%) than in other adult inpatient (11.4%; P = 0.08) and outpatient isolates (11.9%; P > 0.1). Similarly, reduced susceptibility was more common in isolates responsible for hospital-acquired infections (30.9%) than in other adult inpatient (21.0%; P = 0.04) and outpatient (21.4%; P = 0.06) isolates. Isolates from pediatric patients were less likely to be resistant (1.3 versus 12.0%; P < 0.01) but were nearly as likely to have reduced susceptibility (17.7 versus 21.9%; P > 0.1) as nonpediatric isolates. There was an inverse relationship in the proportion of isolates that were resistant versus the proportion that had reduced susceptibility among isolates from individual hospitals (R = 0.031; P < 0.05). In an analysis of isolates from two hospitals, all 9 resistant strains possessed double point mutations in gyrA and all 19 strains with reduced susceptibility strains had single point mutations; no mutations were found among fully susceptible strains. Risk factors for resistance included underlying cancer (odds ratio [OR], 83; 95% confidence interval [CI(95)], 7.3 to 2,241; P < 0.001), exposure to a quinolone (OR, undefined; P = 0.02), and exposure to a nonquinolone antibiotic (OR, 20; CI(95), 2.2 to 482; P < 0.001); underlying cancer was the only independent risk factor (OR, 83; CI(95), 8.6 to 807; P < 0.001). There were no significant associations between any of these factors and reduced susceptibility. Whereas acute and chronic quinolone use in cancer patients is a major selective pressure for resistance, other undetermined but distinct selective pressures appear to be more responsible for reduced susceptibility to fluoroquinolones in E. coli.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600360      PMCID: PMC90786          DOI: 10.1128/AAC.45.11.3084-3091.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.

Authors:  H Wang; J L Dzink-Fox; M Chen; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104.

Authors:  K Mølbak; D L Baggesen; F M Aarestrup; J M Ebbesen; J Engberg; K Frydendahl; P Gerner-Smidt; A M Petersen; H C Wegener
Journal:  N Engl J Med       Date:  1999-11-04       Impact factor: 91.245

3.  The use of antibiotics critical to human medicine in food-producing animals in Taiwan.

Authors:  L C McDonald; M T Chen; T L Lauderdale; M Ho
Journal:  J Microbiol Immunol Infect       Date:  2001-06       Impact factor: 4.399

4.  Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin.

Authors:  P Pieroni; J Goodfellow; L Reesor; M Louie; A E Simor
Journal:  J Antimicrob Chemother       Date:  1997-03       Impact factor: 5.790

5.  Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment.

Authors:  J Wain; N T Hoa; N T Chinh; H Vinh; M J Everett; T S Diep; N P Day; T Solomon; N J White; L J Piddock; C M Parry
Journal:  Clin Infect Dis       Date:  1997-12       Impact factor: 9.079

Review 6.  Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea.

Authors:  J H Yoo; D H Huh; J H Choi; W S Shin; M W Kang; C C Kim; D J Kim
Journal:  Clin Infect Dis       Date:  1997-12       Impact factor: 9.079

7.  Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli.

Authors:  W V Kern; M Oethinger; A S Jellen-Ritter; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Invasive disease caused by ciprofloxacin-resistant uropathogenic Escherichia coli.

Authors:  R Blázquez; A Menasalvas; I Carpena; C Ramírez; C Guerrero; S Moreno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-07       Impact factor: 3.267

9.  Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli.

Authors:  J Ena; C Amador; C Martinez; V Ortiz de la Tabla
Journal:  J Urol       Date:  1995-01       Impact factor: 7.450

10.  Epidemiology of quinolone resistance. Eastern hemisphere.

Authors:  J Turnidge
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more
  22 in total

1.  Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe.

Authors:  Hedi Mammeri; Marc Van De Loo; Laurent Poirel; Luis Martinez-Martinez; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.

Authors:  Pinyo Rattanaumpawan; Irving Nachamkin; Warren B Bilker; Jason A Roy; Joshua P Metlay; Theoklis E Zaoutis; Ebbing Lautenbach
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

3.  Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Authors:  Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2013-08-23       Impact factor: 3.254

4.  The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Xiangqun Mao; Xiaoyan Han; Neil O Fishman; Warren B Bilker; Pam Tolomeo; Mary Wheeler; Irving Nachamkin
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

5.  Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.

Authors:  James A McKinnell; Nicholas S Stollenwerk; Chin W Jung; Loren G Miller
Journal:  Mayo Clin Proc       Date:  2011-05-16       Impact factor: 7.616

6.  Amino acid substitutions in GyrA of Burkholderia glumae are implicated in not only oxolinic acid resistance but also fitness on rice plants.

Authors:  Yukiko Maeda; Akinori Kiba; Kouhei Ohnishi; Yasufumi Hikichi
Journal:  Appl Environ Microbiol       Date:  2006-12-28       Impact factor: 4.792

Review 7.  Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae.

Authors:  Agnese Lupo; Krisztina M Papp-Wallace; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-03       Impact factor: 2.803

Review 8.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

9.  Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007.

Authors:  L Blaettler; D Mertz; R Frei; L Elzi; A F Widmer; M Battegay; U Flückiger
Journal:  Infection       Date:  2009-12       Impact factor: 3.553

10.  Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli.

Authors:  K Huotari; E Tarkka; V Valtonen; E Kolho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-18       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.